Springworks Therapeutics, Inc., A Healthcare Company Of Merck Kgaa, Darmstadt, Germany

This study tests the drug nirogacestat in 50 premenopausal women (ages 18-40) with desmoid tumors, a rare type of non-cancerous growth. The main goal is to see how the drug affects ovarian function and to monitor any side effects. Participants will take the drug and be followed f…

This program provides nirogacestat to individual patients with serious desmoid tumors or NOTCH gene mutation positive tumors who have no other treatment options and cannot join a clinical trial. The goal is to control the disease when standard therapies have failed. Approval is n…

This early-phase study tests a new oral drug, SW-682, in adults with advanced solid tumors that have not responded to standard treatments. The study focuses on cancers with specific genetic changes in the Hippo pathway. The goal is to find a safe dose and see if the drug can shri…

This program provides mirdametinib to individual patients with severe, life-threatening conditions like NF1-related tumors or MAP-K pathway diseases who have no other treatment options and cannot join a clinical trial. Each case requires approval from the company, ethics board, a…

This study looks at how the drug mirdametinib is absorbed and removed from the body in people with moderate or severe liver problems compared to those with healthy livers. It involves 32 adults aged 18 to 80. The goal is to gather information, not to treat any condition.